726 related articles for article (PubMed ID: 12714745)
1. Initiation and synergistic fibrillization of tau and alpha-synuclein.
Giasson BI; Forman MS; Higuchi M; Golbe LI; Graves CL; Kotzbauer PT; Trojanowski JQ; Lee VM
Science; 2003 Apr; 300(5619):636-40. PubMed ID: 12714745
[TBL] [Abstract][Full Text] [Related]
2. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
[TBL] [Abstract][Full Text] [Related]
3. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
[TBL] [Abstract][Full Text] [Related]
4. Following the leader: fibrillization of alpha-synuclein and tau.
Frasier M; Wolozin B
Exp Neurol; 2004 Jun; 187(2):235-9. PubMed ID: 15144849
[No Abstract] [Full Text] [Related]
5. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
6. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
[TBL] [Abstract][Full Text] [Related]
7. Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy.
Giasson BI; Mabon ME; Duda JE; Montine TJ; Robertson D; Hurtig HI; Lee VM; Trojanowski JQ
Acta Neuropathol; 2003 Sep; 106(3):243-50. PubMed ID: 12811584
[TBL] [Abstract][Full Text] [Related]
8. PA700, the regulatory complex of the 26S proteasome, interferes with alpha-synuclein assembly.
Ghee M; Melki R; Michot N; Mallet J
FEBS J; 2005 Aug; 272(16):4023-33. PubMed ID: 16098186
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein.
Mishizen-Eberz AJ; Norris EH; Giasson BI; Hodara R; Ischiropoulos H; Lee VM; Trojanowski JQ; Lynch DR
Biochemistry; 2005 May; 44(21):7818-29. PubMed ID: 15909996
[TBL] [Abstract][Full Text] [Related]
10. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
Popescu A; Lippa CF; Lee VM; Trojanowski JQ
Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
[TBL] [Abstract][Full Text] [Related]
11. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
Duda JE; Giasson BI; Mabon ME; Miller DC; Golbe LI; Lee VM; Trojanowski JQ
Acta Neuropathol; 2002 Jul; 104(1):7-11. PubMed ID: 12070658
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha-tocopherol on an animal model of tauopathies.
Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
[TBL] [Abstract][Full Text] [Related]
13. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Lee VM; Giasson BI; Trojanowski JQ
Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
[TBL] [Abstract][Full Text] [Related]
14. Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation.
Benussi L; Ghidoni R; Paterlini A; Nicosia F; Alberici AC; Signorini S; Barbiero L; Binetti G
Exp Cell Res; 2005 Aug; 308(1):78-84. PubMed ID: 15904919
[TBL] [Abstract][Full Text] [Related]
15. Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast.
Zabrocki P; Pellens K; Vanhelmont T; Vandebroek T; Griffioen G; Wera S; Van Leuven F; Winderickx J
FEBS J; 2005 Mar; 272(6):1386-400. PubMed ID: 15752356
[TBL] [Abstract][Full Text] [Related]
16. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.
Frasier M; Walzer M; McCarthy L; Magnuson D; Lee JM; Haas C; Kahle P; Wolozin B
Exp Neurol; 2005 Apr; 192(2):274-87. PubMed ID: 15755545
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration.
Li HT; Lin DH; Luo XY; Zhang F; Ji LN; Du HN; Song GQ; Hu J; Zhou JW; Hu HY
FEBS J; 2005 Jul; 272(14):3661-72. PubMed ID: 16008565
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein and transgenic mouse models.
Fernagut PO; Chesselet MF
Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
[TBL] [Abstract][Full Text] [Related]
20. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
Murray IV; Giasson BI; Quinn SM; Koppaka V; Axelsen PH; Ischiropoulos H; Trojanowski JQ; Lee VM
Biochemistry; 2003 Jul; 42(28):8530-40. PubMed ID: 12859200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
